A monoclonal antibody (BA11) has been produced against Clostridium botulinum type A neurotoxin by the fusion of myeloma cells (P3 NS1/1-Ag4-1) with spleen cells from BALB/c mice immunized with botulinum type A neurotoxoid. The antibody bound specifically to botulinum type A neurotoxin, showing no cross-reactivity with types B and E botulinum toxins or with any of several other bacterial toxins tested. The monoclonal antibody did not bind to botulinum type A neurotoxin which had been denatured with sodium dodecyl sulfate and bound only weakly to each of the separated heavy and light subunits of the neurotoxin, suggesting a conformational requirement for the antigenic determinant of the antibody. A sensitive immunoassay for C. botulinum type A toxin with monoclonal antibody BAll in conjunction with an enzyme amplication system has been developed which allows detection of 5 to 10 mouse 50% lethal doses ml-' of purified neurotoxin. The assay was equally sensitive when applied to the detection of crude toxin in food stuffs; the average value for the minimum level of detectable toxin in extracts of tinned salmon or corned beef was 9 + 3.1 mouse 50% lethal doses ml 1.
The neurotoxins produced by the eight types of Clostridium botulinum act primarily at the neuromuscular junction and cause the syndrome botulism, which is frequently a fatal condition in humans and animals (13, 14) . Much effort has been imparted by the food industry to ensure the adequacy of food treatment processes to prevent the growth and toxin production of C. botulinum, and there is considerable need for rapid, sensitive assays for these toxins that do not require the use of laboratory animals.
Acute toxicity tests in mice (12) presently provide the only assay for botulinum toxins of sufficient sensitivity to allow the detection of low levels (<5 mouse 50% lethal doses [MLD50s] ml-') in food stuffs and biological samples. Assays involving intraperitoneal injection of toxin take up to 4 days to complete, and although direct injection into a tail vein can shorten the assay time to a few hours, the latter procedure requires considerable operator skill and is tedious to perform and monitor. Furthermore, mouse toxicity results are not in themselves specific; specificity is only imparted by carrying out parallel toxin neutralization tests with homologous antisera. Enzyme-linked immunosorbent assays (ELISAs) developed for botulinum toxins (1, 7, 9-11), although they provide relatively rapid and specific assays for these toxins, are at present insufficiently sensitive to replace the mouse bioassay.
Hybridoma cell lines which secrete antibody specific to a toxin provide a potentially inexhaustable supply of antibody which may be used in ELISAs. In this report, we describe the properties of a monoclonal antibody produced against C. botulinum neurotoxin and its use in an amplified ELISA for the toxin with a lower limit of detectable toxin approaching that of the mouse bioassay. MATERIALS Purification of C. botulinum neurotoxins. C. botulinum type A neurotoxin (specific toxicity, 2 x 108 MLD50s mg of protein-') was purified by previously described methods (5) including affinity chromatography on p-aminophenyl-P-Dthiogalactopyranoside-Sepharose-4B (8) followed by chromatography on DEAE-Sephacel at pH 7.9.
The purification of C. botulinum type B neurotoxin was identical to that described for type A neurotoxin, except for the final purification. Affinity-purified type B neurotoxin (8 x 109 MLD50s) was dialyzed against Tris-hydrochloride buffer (0.1 M, pH 7.9) and loaded onto a column of DEAESephacel (10 by 0.6 cm) equilibrated in the same buffer. Type B neurotoxin (specific toxicity, 1.1 x 108 MLD50s mg of protein-') was eluted from the column with 0.15 M Trishydrochloride (pH 7.9) containing 18 mM NaCl. Impure C. botulinum type E neurotoxin was obtained by the method described for type A neurotoxin (5) . To purify the neurotoxin component, impure toxin (7 x 9 weeks by both intraperitoneal (50 pg, 0.5 ml) and intravenous injection (50 pg, 0.3 ml). Mice were sacrificed 4 days after the final dose, and their spleens were removed.
Spleen cells were fused with myeloma cells (P3 NSI/1-Ag4-1) with polyethylene glycol, and the resulting hybridomas were cloned twice by limiting dilution by methods previously described (6) .
To obtain antibody at high concentration, approximately 107 hybridoma cells were inoculated into the peritoneal cavity of BALB/c mice previously primed with pristane; ascitic fluid was collected 10 to 20 days later. Antibody was purified from ascites fluids by affinity chromatography on protein A-Sepharose (4).
Analytical techniques. Ouchterlony double immunodiffusion with a range of antimouse immunoglobulin subclass sera (immunoglobulin M [IgM], IgA, IgGl, IgG2a, IgG2b, IgG3; Miles Laboratories, Inc.) and sodium dodecyl sulfatepolyacrylamide gel electrophoresis on polyacrylamide slab gels (4 to 30% acrylamide; PAA/4/30; Pharmacia Fine Chemicals) were carried out as described previously (15) .
Isoelectric focusing was performed on precast thin-layer polyacrylamide gels (Ampholine Pagplate, pH 3.5 to 9.5; LKB Bromma) by using a LKB Multiphor apparatus with 1 M H3PO4 as the anode electrode solution and 1 M NaOH at the cathode electrode. After electrophoresis, gels were fixed in 0.7 M trichloroacetic acid-0.14 M 5-sulphosalicyclic acid for 1 h, stained with 0.1% Coomassie blue R250 in 25% (vol/vol) ethanol-8% (vol/vol) acetic acid, and destained in 25% (vol/vol) methanol-8% (vol/vol) acetic acid.
Toxin neutralization test. Antibody ascites fluids (0.1 ml, containing 5 to 10 mg of antibody ml-') were mixed with dilutions of C. botulinum type A neurotoxin (0.25 ml, 5 to 5,000 mouse MLD50s ml-') in 0.07 M sodium phosphate buffer (pH 6.5) containing 0.2% gelatin, incubated for 1 h at 30°C, and diluted to 2.5 ml with the same buffer; 0. Preparation of alkaline phosphatase-conjugated guinea-pig antibotulinum type A toxin. Guinea pigs were immunized by intramuscular injection of (1 ml, 100 ,g) neurotoxoid in Freund complete adjuvant followed by futher doses (100 ,ug) in Freund incomplete adjuvant at 2, 6, 10, and 14 weeks. Immunoglobulins were precipitated from the guinea pig serum by slow addition of an equal volume of 80% saturated ammonium sulfate solution (pH 7.0). After centrifugation at 20,000 x g for 15 min, the precipitate was dissolved in phosphate buffer (0.1 M, pH 6.8; 5 ml ml of original serum 1), and the precipitation process was repeated. The precipitate was then resuspended in phosphate buffer (0.075 M, pH 6.8; 0.5 ml ml of original serum-1), dialyzed against 4 liters of the same buffer at 4°C, and mixed with DEAE Sephacel (0.2 g ml of original serum-') equilibrated in the phosphate buffer. After stirring for 20 min, the supernatant was obtained by centrifugation at 15,000 x g for 10 min, aliquoted, and stored frozen at -20°C.
Conjugation of 2-ml aliquots of guinea pig IgG fraction ( (Table 1) . Antibody BAll bound specifically to C. botulinum type A neurotoxin and showed no cross-reactivity with type B and E neurotoxins or with any other toxin tested. Similar high specificity was also observed with homologous polyclonal antisera used in this study and elsewhere (10) .
Using similar assays, the binding of monoclonal antibody BAll to the separated heavy (100,000-dalton) and light (50,000-dalton) subunits of botulinum type A neurotoxin was assessed (Fig. la) . There was a strong reaction between the antibody and the native toxin, whereas both the separated neurotoxin subunits gave only a weak response in the ELISA with signals that plateaued at absorbance values below 0.1 in each case. In a control experiment, native toxin and both subunits each reacted strongly with homologous mouse polyclonal antisera (Fig. lb) .
The comparatively weak binding of the antibody to the individual toxin subunits implies that the structure of the antigenic site on the native toxin is largely destroyed during the separation of the subunits. This suggests that the antigenic determinant involved is of the discontinuous type, i.e., one in which the epitope comprises amino acid sequences that are separated in the primary sequence of the neurotoxin but are brought together as a consequence of the tertiary structure of the protein. Consistent with this possibility is the fact that denaturation of the neurotoxin with sodium dodecyl sulfate and 2-mercaptoethanol abolishes the antibody-toxin reaction (Table 1) . Ascites fluid (containing ca. 5 mg of antibody ml-1) derived from BAll hybridoma cell line failed to precipitate botulinum type A neurotoxin in double immunodiffusion tests but did display weak toxin-neutralizing activity; 0.1 ml of BAll ascites neutralized approximately 50 MLD50s of botulinum type A neurotoxin. This weak neutralizing activity may be an indication that the antibody-binding site(s) is not on or close to a biologically active region of the molecule. The inability of BAll to precipitate the toxin may reflect the presence of a single binding site for the antibody on the neurotoxin molecule but could equally be due to BAll being monovalent or unable to form the necessary lattice structures because of steric hindrance.
An amplified ELISA developed for the detection of botulinum type A toxin is depicted in Fig. 2 . Each molecule of NAD+ generated by the antibody-alkaline phosphatase conjugate initiates the formation of several hundred colored formazan molecules thus providing an amplification factor.
With this amplified ELISA, three separate determinations of purified C. botulinum type A neurotoxin (specific toxicity, 1 .5 x 108 MLD50s mg of protein-'), gave values for the lowest detectable level of toxin of 5, 7, and 10 MLD50s ml-1.
Determination of toxin by using a conventional singlesandwich assay similar to that depicted in Fig. 2 but with guinea pig anti-botulinum peroxidase conjugate (5-amino salicylic acid as substrate) in place of the alkaline phosphatase system gave a lower limit of detectable toxin of between 300 and 1,000 MLD50s ml-1 (C. Shone, unpublished data).
Thus, the enzyme amplification system afforded almost a corned beef were artificially contaminated with either clostridial spores or portions of culture supernatant; toxin present in food extracts was determined with the mouse bioassay and the immunoassay. Figure 3 shows the results of a typical assay for botulinum toxin in salmon extract in which approximately 10 MLD50s ml-could be detected by the ELISA. Nine determinations of botulinum toxin food extracts ( (1) has the additional drawback that nontoxic proteins of type A C. botulinum also appear to be detected, which may increase the possibility of false-positive reactions occurring in the ELISA.
The amplified immunoassay described in this report provides a convenient test for C. botulinum type A toxin with a sensitivity approximately 10-fold greater than that of the previously reported in vitro assays. At the arbitrary endpoint value of 0.3 absorbance units above background levels, an endpoint easily discernible by eye, approximately 9 MLD50s ml-1' could be detected in the foodstuffs tested, which is equivalent to detection of less than 1 MLD50 in the 0.1-ml portion used for the immunoassay. Compared with the sensitivity of the mouse bioassay (2 MLD50s ml-', assuming 0.5 ml of toxin injected per mouse) the sensitivity of the amplified ELISA is only fivefold lower and as such is sufficiently sensitive to replace the mouse assay in a majority of food industrial and laboratory applications. This could greatly reduce the usage of mice in the detection and quantitation of type A toxin. The ELISA has the additional advantage in that a result can be obtained in less than 6 h compared with the 4 days necessary for the intraperitoneal mouse lethality test which is so widely used at present.
In conclusion, monoclonal antibody BAll appears to be a useful reagent for the detection of botulinum type A toxin in foods. The antibody appears specific to C. botulinum type A neurotoxin and, when used in conjunction with the ELISA amplification system developed by IQ Bio Ltd., provides an immunoassay for the toxin with a sensitivity approaching that of the mouse bioassay.
Monoclonal antibodies are presently being produced in this laboratory against C. botulinum type B, E, and F neurotoxins, which will allow the development of equally sensitive immunoassays for these toxins.
